BURLINGTON, Ontario – (BUSINESS WIRE) – Element Nutritional Sciences Inc. (CSE: ELMT; FRANKFURT: 93X) (the “Company” or “Element”) is pleased to announce that Christine Mazurk-Fera is joining the existing medical advisors, Dr. Jonathan Sherbino and. Dr. Scott McKenzie to form a medical advisory board.
“Our flagship Rejuvenate ™ branded products have gained acceptance by very large retailers in the US and Canada to help consumers reduce the effects of muscle loss with a patented herbal amino acid formulation. While the consumer market is a multi-billion dollar market, there remains a significant opportunity in the institutional market composed of medical professionals and medical institutions to develop higher dosage Rejuvenate ™ formulations to prevent orthopedic and oncological patients with muscle loss and / or atrophy or that require accelerated recovery from medical procedures. The global oncology therapy market is $ 158 billion1 and we have the potential to use our patented formulation to help improve patient outcomes. Our newly formed Medical Advisory Board will be instrumental in helping Element develop a research and development strategy to develop these new Rejuvenate ™ formulations and bring them to market, ”said Stuart Lowther, Chief Executive Officer.
Dr. Jonathan Sherbino, B.Sc., MD MEd FRCPC FAcadMEd DRCPSC (CE)
Dr. Sherbino is an emergency doctor and head of the trauma team. He is Assistant Dean, Health Professions Education Research, Faculty of Health Sciences, and Professor of Medicine at McMaster University. Jonathan is the former chairman of the Specialty Committee for Emergency Medicine for the Royal College of Physicians & Surgeons of Canada. He has published more than 150 essays and four books. He has given numerous national and international plenary and keynote lectures in research areas such as cardiac biomarkers and clinical decision-making rules for cardiac arrest. Most recently, Dr. Sherbino received the 3M National Teaching Fellowship Award for groundbreaking work as a medical educator, Canada’s most prestigious recognition for excellence in educational leadership and teaching at the post-secondary level.
Christine Mazurk-Fera
Ms. Mazurk-Fera has over two decades of leadership experience in the medical sector focused on strategic leadership, product development, marketing clinical quality excellence and improving patient outcomes. Christine is currently a member of the Advisory Committee of the Cribwolf Foundation, most recently was Director, Clinical Quality Assurance at Mohawk Medbuy Corporation and previously held various management positions, including global marketing and corporate accounts, at Teleflex, a global medical technology provider, for almost 20 years.
Dr. Scott McKenzie, M.Sc., MD, FRCS (C)
Dr. McKenzie is a Fellow of the Royal College of Canada, Orthopedic Surgery and has practiced orthopedic surgery since 2001. Since 2006, Dr. McKenzie as an orthopedic surgeon at the Royal Victoria Hospital in Barrie, Ontario. He is also currently an Associate Professor at McMaster University and the University of Toronto.
In connection with her appointment, Christine Mazurk-Fera was granted 250,000 options in the Company at a price of 0.81 per option for a period of five years. The options vest 25% immediately and 25% each on the first, second and third anniversary of this agreement.
About element
Element is an innovative, research-driven Canadian nutraceutical company specializing in developing science-based products for the global consumer goods market, with a portfolio specifically for men and women over 50. Element’s lead product, Rejuvenate ™, is a proprietary formulation that clinically proven to help rebuild, restore and rejuvenate the natural loss of muscle mass due to aging or other medical conditions. Element also offers JAKTRX ™, an elite brand of performance supplements. Element was founded in 2015 and is based in Burlington, Ontario.
To learn more about Element, visit elmtinc.com.
For more information on Rejuvenate ™, please visit: www.rejuvenatemuscle.com
Forward-Looking Statements
This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than historical facts, are forward-looking statements and are based on expectations, estimates and projections as of the date of this press release. Any statement that includes discussion of predictions, expectations, beliefs, plans, projections, goals, assumptions, future events or performance (often, but not always, with phrases such as “expected” or “does not expect”, “is expected”, “Anticipates” or “does not expect”, “planet”, “budget”, “planned”, “forecast”, “estimates”, “believes” or “intends” or variations of such words and phrases or indicates that certain actions, Events or results “could” or “could”, “would”, “could” or “will” occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this press release, forward-looking statements relate to, among other things, the extent of the institutional market opportunity for Rejuvenate ™ and the Company’s ability to develop a product for the orthopedic and oncology markets.
These forward-looking statements are based on reasonable assumptions and estimates made by the company’s management at the time these statements were made. Actual future results could differ materially because forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the company’s actual results, performance or accomplishments to differ materially from future results, performance or achievements expressed or achieved therein Forward-looking statements are implied. These factors include, but are not limited to: fluctuations in general macroeconomic conditions; Expectations regarding the size of the health, nutraceutical and wellness markets in the US and Canada and changing consumer habits; the viability of the company’s products; Availability of sales channels for the company’s product offerings; the company’s ability to successfully achieve its business objectives; Expansion plans; successful development of the company’s proposed products; the existence of laws and regulations that may restrict or recall the company’s products in the United States and Canada; Customer and sales relationships; Fluctuations in the securities markets; and the company’s inability to obtain adequate insurance to cover risks and hazards. Although the forward-looking statements contained in this press release are based on assumptions that the company’s management believes or at the time believed to be reasonable, the company cannot assure shareholders that actual results will correspond to these forward-looking statements. as there may be other factors that cause results not to be as expected, estimated or intended. Readers are cautioned not to place undue reliance on the forward-looking statements and information in this press release. The company assumes no obligation to update any forward-looking statements of beliefs, opinions, projections or other factors should they change, unless required by law.
No stock exchange, securities commission or other regulatory authority has approved or rejected the information contained herein.
1 Mordor Intelligence, Global Cancer Therapy Market 2021-2026.
